Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Robert Coffin"'
Autor:
Anna Olsson-Brown, Mohammed M. Milhem, P.K. Bommareddy, Andrea Pirzkall, S. Samakoglu, Francesca Aroldi, L. Menezes, Adel Samson, Jiaxin Niu, Robert Coffin, Jason Chesney, Ari M. Vanderwalde, Scott Baum, Brendan D. Curti, Mark R. Middleton, T.L. Bowles, Terence Duane Rhodes, Joseph J. Sacco, K.J. Harrington, Douglas Earl Laux
Publikováno v:
Annals of Oncology. 32:S903-S904
Autor:
Ke Liu, Steve H. Thorne, Daniel A. Saltzman, Peter Tattersall, Grant McFadden, Liang Deng, Balveen Kaur, Laura Evgin, Steve Fiering, Richard G. Vile, Sheryl Ruppel, Herbert Kim Lyerly, Robert M. Hoffman, James L. Gulley, Robert Coffin, Matthew Giacalone, Claudia Gravekamp, Ariel E. Marciscano, Halle Huihong Zhang, Neil S. Forbes, Eddie Moradian, Shibin Zhou, Hal Gunn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-24 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy
Autor:
Robert Coffin
Publikováno v:
Immunotherapy. 8:103-106
Interviewed by Ellen Clarke, Commissioning Editor, Future Science Group. Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999. He wa
Autor:
Howard Goldsweig, Thomas Amatruda, Howard L. Kaufman, Tony Reid, Mike Nemunaitis, Neil Senzer, Gregory Daniels, John A. Glaspy, Tracey Marshall, John Nemunaitis, Rene Gonzalez, Colin Love, Eric D. Whitman, Robert Coffin, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 27:5763-5771
Purpose Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease. Patients and Methods Trea
Autor:
Neil Senzer, Igor Puzanov, Bin Yao, Gerald P. Linette, Lynn E. Spitler, Sanjiv S. Agarwala, Susan Doleman, Troy H. Guthrie, Jason Chesney, Ari M. Vanderwalde, Robert Coffin, Keith A. Delman, Lee D. Cranmer, Kevin J. Harrington, Karl D. Lewis, Gregory A. Daniels, Jennifer Gansert, Jonathan S. Zager, Merrick I. Ross, Brendan D. Curti, Ai Li, Mark R. Middleton, Howard L. Kaufman, Wilson H. Miller, Mohammed M. Milhem, Thomas Amatruda, Yining Ye, Frances A. Collichio, Robert H.I. Andtbacka
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(25)
Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic anti
Autor:
Lynn E. Spitler, Howard L. Kaufman, Robert H.I. Andtbacka, Ai Li, Mohammed M. Milhem, Jason Chesney, Robert Coffin, Mark Shilkrut, Mark R. Middleton, Kevin J. Harrington, Frances A. Collichio, Neil Senzer, Keith A. Delman, Igor Puzanov, Sanjiv S. Agarwala, Thomas Amatruda
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM, a randomized Phase III trial o
Autor:
Jason Chesney, Kevin J. Harrington, Kate Liu, Mark Shilkrut, S. Fourie, Frances A. Collichio, Lydia Dreosti, N.M. Steven, Robert Coffin, John Nemunaitis, Robert H.I. Andtbacka, Ai Li, Thomas Amatruda, Merrick I. Ross, Howard L. Kaufman
Publikováno v:
Annals of Oncology. 25:iv382
Aim: T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune responses. Compared to GM-CSF alone, T-VEC significantly improved durable response rate (DRR; p
Autor:
Keith A. Delman, Frances A. Collichio, Lynn E. Spitler, Ai Li, Merrick I. Ross, Igor Puzanov, Yining Ye, Thomas Amatruda, Robert H.I. Andtbacka, Robert Coffin, Howard L. Kaufman, Jennifer Gansert, Neil Senzer, Jason Chesney
Publikováno v:
Journal of Clinical Oncology. 32:9008a-9008a
9008a Background: T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune re...
Autor:
Howard L. Kaufman, Yining Ye, Ari M. Vanderwalde, Robert H.I. Andtbacka, Neil Senzer, Frances A. Collichio, Thomas Amatruda, Keith A. Delman, Igor Puzanov, Robert Coffin, Lynn E. Spitler, Susan Doleman, Jason Chesney
Publikováno v:
Journal of Clinical Oncology. 31:LBA9008-LBA9008
LBA9008 Background: T-VEC is an oncolytic immunotherapy (OI) derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM is a randomized, phase I
Publikováno v:
Journal of Clinical Oncology. 30:e14546-e14546
e14546 Background: T-VEC is an investigational, immune-enhanced oncolytic herpes simplex virus type I that selectively replicates in solid tumors. This was an open-label, dose-escalation study of T-VEC administered by endoscopic ultrasound (EUS)-guid